Tech Company Financing Transactions
Be Biopharma Funding Round
On 10/23/2024, Be Biopharma raised $82 million in funding from Alta Partners, Arch Venture Partners and Atlas Venture.
Transaction Overview
Company Name
Announced On
10/23/2024
Transaction Type
Venture Equity
Amount
$82,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to achieve clinical proof of concept for BE-101 and to advance the development of BE-102.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. B200 # 001
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Be Bio is a leader in developing engineered B cells as a new category of cellular medicines. B cells are one of the most unique and versatile populations of cells in the body, playing a key role in humoral immunity and in modulating immune cell behavior in tumors and chronically inflamed tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Steinberg
Co-Founder
Lea Hachigian
President
Aleks Radovic-Moreno
Browse more venture capital transactions:
Prev: 10/23/2024: Tennr venture capital transaction
Next: 10/23/2024: Archy venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs